• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

​​​​​​​Journal of Medical Viroligy - Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic

sharon sanders

Editor-in-Chief & President
RESEARCH ARTICLE

Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic

Yee Hui Yeo,Maggie Wang,Xinyuan He,Fan Lv,Yue Zhang,Jian Zu,Mei Li,Yang Jiao,Joseph E. Ebinger,Jignesh K. Patel,Susan Cheng,Fanpu Ji
First published: 29 September 2022

https://doi.org/10.1002/jmv.28187
Yee Hui Yeo, Maggie Wang, and Xinyuan He contributed equally to this study.

Susan Cheng and Fanpu Ji are co-senior authors.
Read the full text
PDF
TOOLS

SHARE

Abstract


The COVID-19 pandemic has had a detrimental impact on the healthcare system. Our study armed to assess the extent and the disparity in excess acute myocardial infarction (AMI)-associated mortality during the pandemic, through the recent Omicron outbreak. Using data from the CDC's National Vital Statistics System, we identified 1 522 669 AMI-associated deaths occurring between 4/1/2012 and 3/31/2022. Accounting for seasonality, we compared age-standardized mortality rate (ASMR) for AMI-associated deaths between prepandemic and pandemic periods, including observed versus predicted ASMR, and examined temporal trends by demographic groups and region. Before the pandemic, AMI-associated mortality rates decreased across all subgroups. These trends reversed during the pandemic, with significant rises seen for the youngest-aged females and males even through the most recent period of the Omicron surge (10/2021–3/2022). The SAPC in the youngest and middle-age group in AMI-associated mortality increased by 5.3% (95% confidence interval [CI]: 1.6%–9.1%) and 3.4% (95% CI: 0.1%–6.8%), respectively. The excess death, defined as the difference between the observed and the predicted mortality rates, was most pronounced for the youngest (25–44 years) aged decedents, ranging from 23% to 34% for the youngest compared to 13%–18% for the oldest age groups. The trend of mortality suggests that age and sex disparities have persisted even through the recent Omicron surge, with excess AMI-associated mortality being most pronounced in younger-aged adults.


CONFLICTS OF INTEREST


Dr. S. Cheng has received consulting fees from Zogenix outside of the submitted work. Dr. F. Ji has received speaker fees from Gilead Sciences, MSD, and Ascletis, in addition to consulting or advisory board fees from Gilead and MSD, all outside of the submitted work. The remaining authors declare no conflict of interest.

https://onlinelibrary.wiley.com/doi/10.1002/jmv.28187
 
Back
Top Bottom